These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
306 related articles for article (PubMed ID: 24099328)
21. Nasal-to-CNS drug delivery: where are we now and where are we heading? An industrial perspective. Landis MS; Boyden T; Pegg S Ther Deliv; 2012 Feb; 3(2):195-208. PubMed ID: 22834197 [TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetic considerations for targeted drug delivery. Yamashita F; Hashida M Adv Drug Deliv Rev; 2013 Jan; 65(1):139-47. PubMed ID: 23280371 [TBL] [Abstract][Full Text] [Related]
23. Bioinspired Platform Conjugated Active Drug Delivery. Shao J; Xuan M; He Q; Dai L Curr Drug Targets; 2018 Feb; 19(4):328-338. PubMed ID: 27262485 [TBL] [Abstract][Full Text] [Related]
24. In silico ADME-Tox modeling: progress and prospects. Alqahtani S Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506 [TBL] [Abstract][Full Text] [Related]
25. Nanotechnology-based Drug Delivery, Metabolism and Toxicity. Malaviya P; Shukal D; Vasavada AR Curr Drug Metab; 2019; 20(14):1167-1190. PubMed ID: 31902350 [TBL] [Abstract][Full Text] [Related]
26. A Comprehensive Insight Towards Pharmaceutical Aspects of Graphene Nanosheets. Emadi F; Emadi A; Gholami A Curr Pharm Biotechnol; 2020; 21(11):1016-1027. PubMed ID: 32188383 [TBL] [Abstract][Full Text] [Related]
27. Recent Trends in Nanotechnology-Based Drugs and Formulations for Targeted Therapeutic Delivery. Iqbal HMN; Rodriguez AMV; Khandia R; Munjal A; Dhama K Recent Pat Inflamm Allergy Drug Discov; 2017; 10(2):86-93. PubMed ID: 27978790 [TBL] [Abstract][Full Text] [Related]
28. Advances and challenges of nanotechnology-based drug delivery systems. Jiang W; Kim BY; Rutka JT; Chan WC Expert Opin Drug Deliv; 2007 Nov; 4(6):621-33. PubMed ID: 17970665 [TBL] [Abstract][Full Text] [Related]
29. Nanostructured formulations and drug delivery systems. Bunt CR Pharm Dev Technol; 2018 Apr; 23(4):315. PubMed ID: 29514576 [No Abstract] [Full Text] [Related]
30. Nanostructure-mediated drug delivery. Hughes GA Nanomedicine; 2005 Mar; 1(1):22-30. PubMed ID: 17292054 [TBL] [Abstract][Full Text] [Related]
31. Solid lipid nanoparticles for parenteral drug delivery. Wissing SA; Kayser O; Müller RH Adv Drug Deliv Rev; 2004 May; 56(9):1257-72. PubMed ID: 15109768 [TBL] [Abstract][Full Text] [Related]
32. Chemical structure modifications and nano-technology applications for improving ADME-Tox properties, a review. Farouk F; Shamma R Arch Pharm (Weinheim); 2019 Feb; 352(2):e1800213. PubMed ID: 30609117 [TBL] [Abstract][Full Text] [Related]
33. PEGylated nanomedicines: recent progress and remaining concerns. Vllasaliu D; Fowler R; Stolnik S Expert Opin Drug Deliv; 2014 Jan; 11(1):139-54. PubMed ID: 24295065 [TBL] [Abstract][Full Text] [Related]
34. Influencing Factors of the Pharmacokinetic Characters on Nanopharmaceutics. Ji X; Lu W; Wu K; Cho WC Pharm Nanotechnol; 2017; 5(1):24-31. PubMed ID: 28948908 [TBL] [Abstract][Full Text] [Related]
35. Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system. Bamrungsap S; Zhao Z; Chen T; Wang L; Li C; Fu T; Tan W Nanomedicine (Lond); 2012 Aug; 7(8):1253-71. PubMed ID: 22931450 [TBL] [Abstract][Full Text] [Related]
36. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973 [TBL] [Abstract][Full Text] [Related]
37. Advances in the treatment of neurodegenerative disorders employing nanoparticles. Spuch C; Saida O; Navarro C Recent Pat Drug Deliv Formul; 2012 Apr; 6(1):2-18. PubMed ID: 22272933 [TBL] [Abstract][Full Text] [Related]
38. Drug delivery to the brain--realization by novel drug carriers. Müller RH; Keck CM J Nanosci Nanotechnol; 2004 May; 4(5):471-83. PubMed ID: 15503432 [TBL] [Abstract][Full Text] [Related]
39. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs. Singh SS Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106 [TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and ADME characterizations of antibody-drug conjugates. Lin K; Tibbitts J; Shen BQ Methods Mol Biol; 2013; 1045():117-31. PubMed ID: 23913144 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]